Targacept Receives Grant From Michael J Fox Foundation
To conduct research in treatment of side effects of Parkinson’s disease therapy
Targacept has received a grant of over $600,000 from The Michael J Fox Foundation for Parkinson's Research (MJFF).
The grant, awarded as part of MJFF’s Therapeutics Development, is designed to fund preclinical research involving the use of compounds that modulate neuronal nicotinic receptors, to address Levodopa-induced abnormal involuntary movements (dyskinesias).
Reportedly, the terms of the grant provide for Targacept to receive the funds, as the research is performed over an expected period of one year.
Donald deBethizy, president and CEO of Targacept, said: “We are honored to receive this grant and inspired by MJFF’s commitment to finding new solutions to meet the needs of patients with Parkinson’s disease.”
Related Insight
Suppliers Directory
Farfield Group - Analytical Instrument Systems
Farfield’s proprietary innovation Dual Polarisation Interferometer, (DPI) is an analytical instrument for label free, real time measurement for molecular systems and interactions.
Suppliers
Presspart - Metal and Plastic Drug Delivery Components and Devices
Presspart specialises in bespoke, concept-to-completion, metal and plastic drug delivery components and devices that help pharmaceutical companies deliver drugs of the present and future. With more than 40 years' experience and a worldwide reputation for competence, quality and innovation, Presspart constantly studies, refines and optimises its processes to ensure optimum quality and performance for its customers.
Suppliers
Peptisyntha SA - Leading cGMP Manufacturer of Peptide and Peptidomimetic APIs
Peptisyntha - 'Your Chemistry for Life'
Peptisyntha is a leading cGMP manufacturer of therapeutic peptides (peptide APIs) and peptidomimetics serving customers of the pharmaceutical, biotech, diagnostic and cosmetic industries.
Suppliers Hudson Robotics - Lab Automation Solutions. We produce robots that allow users to easily turn microplate readers into automated screening systems. We have microplate movement and storage systems, as well as liquid handling solutions. We also offer complete workcells for biological research and drug discovery, in which our products are integrated with third party equipment to solve complex laboratory protocols. Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Internet usage of Indian General Practitioners
Published by Kinapse
White Papers
Phenom™ use for pharmaceutical particle inspection
Published by Phenom World
White Papers
MyQUMAS 2011
Published by QUMAS
White Papers
Pipet Controller for the Most Demanding Users
Published by VITLAB®
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.